Package Leaflet: Information for the User
Pazopanib Accord 200 mg film-coated tablets EFG
Pazopanib Accord 400 mg film-coated tablets EFG
Pazopanib is a type of medicine called a protein kinase inhibitor. It works by blocking the activity of proteins involved in the growth and spread of cancer cells.
Pazopanib is used in adults to treat:
Do not take Pazopanib Accord
Talk to your doctorif you think this may apply to you.
Talk to your doctor before taking Pazopanib Accord:
(abnormal passages that form between some parts of the intestine).
Talk to your doctorif you think you may have any of these problems. Your doctor will decide if pazopanib is suitable for you. You may need additional teststo check that your kidneys, heart, and liver are working properly.
Pazopanib may increase your blood pressure. Your doctor will check your blood pressure before taking pazopanib and while you are taking it. If you have high blood pressure, you will receive treatment with medicines that help lower it.
Your doctor will tell you to stop taking pazopanib at least 7 days before your operation, as this may affect wound healing. Your treatment will be restarted when the wounds have healed properly.
Pazopanib may make other conditions worse or cause serious side effects. You should be aware of certain symptoms while taking pazopanib to reduce the risk of any problems. See section 4.
Pazopanib is not recommended in people under 18 years of age. It is not known how it works in this age group. Additionally, it should not be used in children under 2 years of age due to safety concerns.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes herbal medicines and medicines bought without a prescription.
Some medicines may affect how pazopanib works or increase the chance of you experiencing side effects. Pazopanib may also affect how other medicines work. These include:
Talk to your doctor or nurse for more information.
Tell your doctoror pharmacist if you are taking any of these medicines.
Do not take pazopanib with food, as this affects the absorption of the medicine. Take it at least 2 hours after a meal or 1 hour before a meal (see section 3).
Do not drink grapefruit juicewhile being treated with pazopanib, as this may increase the chance of side effects.
Pazopanib is not recommended if you are pregnant. The effect of Pazopanib during pregnancy is not known.
Do not breastfeed while taking pazopanib. It is not known if the components of pazopanib pass into breast milk. Tell your doctor about this.
Male patients(including those who have undergone vasectomy) who have partners who are pregnant or may become pregnant (including those using other contraceptive methods) must use condoms during sexual intercourse, while taking pazopanib and for at least 2 weeks after the last dose.
Fertility may be affectedby treatment with pazopanib. Talk to your doctor about this.
Pazopanib may cause side effects that can affect your ability to drive or use machines.
This medicine contains less than 1 mmol of sodium (23 mg) per film-coated tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, talk to your doctor or pharmacist again.
The normal doseis 800 mg taken once a day. The dose can be taken as 2 tablets of 400 mg or as 4 tablets of 200 mg. The dose of 800 mg once a day is the maximum dose per day. Your doctor may need to reduce your dose if you experience side effects.
Do not take pazopanib with food.Take it at least 2 hours after a meal or 1 hour before a meal. For example, you can take it 2 hours after breakfast or 1 hour before lunch. Take Pazopanib at the same time every day.
Swallow the tablets whole with water, one after the other. Do not break or crush the tablets as this affects the way the medicine is absorbed and may increase the chance of side effects.
If you take more tablets than you should, ask your doctor or pharmacist for advice.If possible, show them the pack or this leaflet.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount ingested.
Do not take a double dose to make up for forgotten doses. Only take your next dose at the usual time.
Take pazopanib for as long as your doctor has recommended. Do not stop treatment unless your doctor advises you to.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Brain inflammation(posterior reversible leukoencephalopathy syndrome).
Rarely, pazopanib can cause brain inflammation, which can be life-threatening. Symptoms include:
Stop taking pazopanib and seek medical attention immediatelyif you experience any of these symptoms or if you have a headache accompanied by any of these symptoms.
Hypertensive crises(sudden and severe increase in blood pressure)
Pazopanib can cause a sudden and severe increase in blood pressure. This is known as a hypertensive crisis. Your doctor will check your blood pressure while you are taking pazopanib. Signs and symptoms of a hypertensive crisis can include:
Stop taking pazopanib and seek medical attention immediatelyif you experience a hypertensive crisis.
The risk of these problems may be greater in people with a heart condition or those taking other medicines. While taking pazopanib, you will be checked for any heart problems.
Cardiac disorder/heart failure, cardiac arrest
Pazopanib can affect the way the heart pumps or increase the chance of having a heart attack.
Symptoms can include:
Seek medical attention immediatelyif you experience any of these symptoms.
Changes in heart rhythm (prolonged QT interval)
Pazopanib can affect the heart rhythm, which in some people can trigger a potentially serious heart condition known as torsade de pointes. This can cause a rapid heartbeat that can lead to loss of consciousness.
Tell your doctorif you notice any unusual change in your heartbeat, such as beats that are too fast or too slow.
Pazopanib can increase the chance of having a stroke. Symptoms of a stroke can include:
Seek medical attention immediatelyif you experience any of these symptoms.
Pazopanib can cause serious bleeding in the digestive system (in the stomach, esophagus, rectum, or intestine), or in the lungs, kidneys, mouth, vagina, or brain, although this is rare. Symptoms can include:
Seek medical attention immediatelyif you experience any of these symptoms.
Pazopanib can cause a hole in the stomach or intestine or the formation of an abnormal connection between two parts of the digestive tract (a fistula). Symptoms can include:
Seek medical attention immediatelyif you experience any of these symptoms.
Pazopanib can cause liver problems that can become serious diseases such as liver failure, which can be fatal. Your doctor will check your liver enzymes while you are taking pazopanib. Signs that your liver may not be working properly can include:
Seek medical attention immediatelyif you experience any of these symptoms.
Deep vein thrombosis (DVT) and pulmonary embolism
Pazopanib can cause blood clots in the veins, especially in the legs (deep vein thrombosis or DVT), which can move to the lungs (pulmonary embolism). Symptoms can include:
Thrombotic microangiopathy (TMA)
Pazopanib can cause blood clots in the small blood vessels of the kidneys and brain, accompanied by a reduction in red blood cells and cells involved in blood clotting (thrombotic microangiopathy, TMA). Symptoms can include:
Seek medical attention immediatelyif you experience any of these symptoms.
Pazopanib can cause rapid destruction of cancer cells, leading to a condition known as tumor lysis syndrome, which can be life-threatening in some people. Symptoms can include irregular heartbeat, seizures, confusion, muscle cramps or spasms, or decreased urine output. Seek medical attention immediatelyif you experience any of these symptoms.
Infections that occur while taking pazopanib can become serious. Symptoms of infections can include:
Seek medical attention immediatelyif you experience any of these symptoms.
Pazopanib can rarely cause lung inflammation (interstitial lung disease, pneumonitis), which can be life-threatening in some people. Symptoms include difficulty breathing or cough that does not go away. You will be checked for any lung problems while taking pazopanib.
Seek medical attention immediatelyif you experience any of these symptoms.
Pazopanib can decrease the amount of thyroid hormone produced in your body. This can cause weight gain and fatigue. Your thyroid hormone levels will be checked while you are taking pazopanib.
Tell your doctorif you notice significant weight gain or fatigue.
Pazopanib can cause the separation or tearing of the back of the eye (retinal detachment or tear). This can cause blurred vision or changes in vision.
Tell your doctorif you notice any change in your vision.
Very common side effects(may affect more than 1 in 10people):
Tell your doctor or pharmacistif any of these side effects become troublesome.
Common adverse effects(may affect up to 1 in 10people):
Inform your doctoror pharmacist if any of these adverse effects become problematic.
Uncommon adverse effects(may affect up to 1 in 100people):
Rare adverse effects(may affect up to 1 in 1,000people):
Frequency not known(cannot be estimated from the available data):
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging after EXP or CAD. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE Point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Pazopanib Accord 200 mg film-coated tablets
Each film-coated tablet contains pazopanib hydrochloride equivalent to 200 mg of pazopanib.
Tablet core: Microcrystalline cellulose (E460), Sodium carboxymethyl starch (type A) (from potato), Povidone (E1201), Magnesium stearate (E470b)
Film coating (Opadry Pink 13B540026): Hypromellose (E464), Titanium dioxide (E171), Macrogol (E1521), Red iron oxide (E172), Polysorbate 80 (E433) (see section 2 "Pazopanib Accord contains sodium").
Pazopanib Accord 400 mg film-coated tablets
Each film-coated tablet contains pazopanib hydrochloride equivalent to 400 mg of pazopanib.
Tablet core: Microcrystalline cellulose (E460), Sodium carboxymethyl starch (type A) (from potato), Povidone (E1201), Magnesium stearate (E470b)
Film coating (Opadry White 13B58802): Hypromellose (E464), Titanium dioxide (E171), Macrogol (E1521), Polysorbate 80 (E433) (see section 2 "Pazopanib Accord contains sodium").
Pazopanib Accord 200 mg film-coated tablets
Pazopanib Accord 200 mg are capsule-shaped, pink, marked with "200" on one side, with approximate dimensions of 14.3 mm x 5.7 mm.
Pazopanib Accord 200 mg is packaged in boxes of 10, 30, 60, or 90 film-coated tablets in transparent PVC/PE/PVDC//Alu blisters,
or
in boxes of 10x1, 30x1, 60x1, or 90x1 film-coated tablets in single-dose perforated transparent PVC/PE/PVDC//Alu blisters.
or
in white HDPE bottles with child-resistant PP closure containing 30 or 90 film-coated tablets and a multiple package containing 90 (3 bottles of 30) film-coated tablets in a box.
Pazopanib Accord 400 mg film-coated tablets
Pazopanib Accord 400 mg are capsule-shaped, white, marked with "400" on one side, with approximate dimensions of 18.0 mm x 7.1 mm.
Pazopanib Accord 400 mg is packaged in boxes of 10, 30, 60, or 90 film-coated tablets in transparent PVC/PE/PVDC//Alu blisters.
or
in boxes of 10x1, 30x1, 60x1, or 90x1 film-coated tablets in single-dose perforated transparent PVC/PE/PVDC//Alu blisters.
or
in white HDPE bottles with child-resistant PP closure containing 30 or 60 film-coated tablets in a box.
Not all pack sizes may be marketed.
Accord Healthcare S.L.U.
World Trade Center
Moll de Barcelona, s/n
Edifici Est, 6ª planta
08039 Barcelona
Spain
Remedica Ltd
Aharnon Street, Limassol Industrial Estate,
Limassol 3056, Cyprus
or
PharOS MT Ltd.
HF62X, Hal Far Industrial Estate,
Birzebbugia BBG3000, Malta
This medicine is authorized in the Member States of the European Economic Area under the following names
Member State | Medicine name |
Hungary | Pazopanib Accord 200/400 mg film-coated tablets |
Bulgaria | Pazopanib Accord 200/400 mg ????????? ???????? |
Czech Republic | Pazopanib Accord |
Croatia | Pazopanib Accord 200/400 mg film-coated tablets |
Poland | Pazopanib Accord |
Romania | Pazopanib Accord 200/400 mg film-coated tablets |
Slovenia | Pazopanib Accord 200/400 mg film-coated tablets |
Slovakia | Pazopanib Accord 200/400 mg film-coated tablets |
Spain | Pazopanib Accord 200/400 mg film-coated tablets |
Italy | Pazopanib Accord |
Portugal | Pazopanib Accord 200/400 mg film-coated tablets |
Greece | Pazopanib Accord 200/400 mg ????????? ????????? |
France | PAZOPANIB ACCORD 200 mg, film-coated tablet PAZOPANIB ACCORD 400 mg, film-coated tablet |
Belgium | Pazopanib Accord 200/400 mg film-coated tablets |
Denmark | Pazopanib Accord 200/400 mg film-coated tablets |
Estonia | Pazopanib Accord |
Finland | Pazopanib Accord 200/400 mg film-coated tablets |
Lithuania | Pazopanib Accord 200/400 mg film-coated tablets |
Latvia | Pazopanib Accord 200/400 mg film-coated tablets |
Netherlands | Pazopanib Accord 200/400 mg film-coated tablets |
Norway | Pazopanib Accord |
Sweden | Pazopanib Accord 200/400 mg film-coated tablets |
Ireland | Pazopanib Accord 200/400 mg film-coated tablets |
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.